ajbhu - you living near Budapests's Disney Castle and dream of...

First 2 Last

Share
Profile

Follow
CroMagnon

264 Posts.

3

07/05/15

20:47

Post #: 15238165
Share

Originally posted by ajbhu ↑

So, this is it.
The meeting took and/or is taking place.

What is the outcome? How large is going to be the proposed clinical trial?
How long will it take?

Is possible to combine the new required European clinical trial with a combined USA FDA clinical trial?
Should be considered!

To have a new fresh start, if this is the case, can we have a US stock listing on the NASDAQ (with Treasury shares to be issued by the company on a ADR basis in the US) and have the market finance both clinical trials? We are in a Phase 2 stage in the USA. We could have a major marketing event and being listed in the US biotech magazines and would have the US speculative investors able to invest in Tissue Therapies.

This would become a US and European event.

Price with a potential demand and a proposed US listing would go up substantially and could reach the estimated US1.
Actually to be listed in the US in the NASDAQ you need to have a price listing above USD 1.

Let's have a thought, but please, let's start to be more market oriented than just researcher oriented. We have to be the next "Wolf of Wall Street".
Anything can be sold, just you need to have the proper person at the proper place and at the proper time and with the proper price able to sell OUR product.

Expand

ajbhu - you living near Budapests's Disney Castle and dream of Disneyland?

What about our Australian roots?
What we need is to talk with NZ and find some Anzac's to storm the Canary Wharf.
Without British generals, of course.

Last edited by CroMagnon: 07/05/15

TIS Price at posting: 8.9¢ Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

RSG

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

ADD

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

MIN

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

WC8

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

HotCopper Highlights: Your most watched stocks for Week 48, 2024

There are more pages in this discussion • 6 more messages in this thread...

First 2 Last

Add TIS (ASX) to my watchlist

ajbhu - you living near Budapests's Disney Castle and dream of...

Top Stories

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Resolute shares bounce back as second payment made to Mali government to secure workers' release

Ice-cold winner: Cryopreserver Vitrafy escapes November's IPO struggles to end debut week higher

Parkes Au-Cu project to 'transform' Adavale Resources with key targets

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Dale Gillham's weekly wrap: Bold moves in NZ, caution in Australia

Week 48 Wrap: ASX flirts with 8,500pts; APRA declines mortgage loan easing; Trump's Bessent tied to Dem donor

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

HotCopper Highlights: Your most watched stocks for Week 48, 2024